NFKB1 and cancer: Moreover, constitutive NF-κB activation due to signaling defects, mutations, or chromosomal rearrangements has been identified in a wide variety of cancers [13,14], and thus the constitutive activation of NF-κB is viewed as an obstacle to effective cancer therapy [15].